Catalonia In Danger Of Failing Pharma Stability Test
Executive Summary
Other companies in the sector could follow Spanish flagship biotech Oryzon and move their headquarters to Madrid, leaving a big hole in the coffers of the Catalan government.
You may also be interested in...
Catalan Biotechs Boosted By International Backers
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.